Literature DB >> 24497727

Genetic Variant of C-5312T Can Change Binding Pattern of Sp1 to Renin Enhancer that are Very Likely to Affect Renin Gene Expression.

Mifetika Lukitasari1, Jayarani F Putri2, Muladefi Choiriyah1, Mohammad Saifur Rohman3, Nashi Widodo2.   

Abstract

Renin distal enhancer plays a pivotal role in renin gene expression, and the genetic variants C-5312T of renin enhancer can affect renin gene transcription level. However, the mechanism associated with the transcription level changes remains unknown. Therefore, it is of interest to investigate the possible role of distal enhancer in regulating the expression of renin gene. Single nucleotide polymorphism in renin distal enhancer was identified in 34 hypertensive patients by automatic sequencing. The data showed that the renin enhancer from the patients have genetic variants C-5312T or C-5312T SNP. Hence, the functionality of the renin enhancer and influence of the genetic variants C-5312T on binding to Sp1 is studied. These results from the binding study suggested that Sp1 binds to the DNA in GC rich region. Thus, the genetic variant C-5312T has changed the binding pattern of Sp1 to renin enhancer. This is likely to influence Sp1 activity to stimulate the expression of renin gene. The binding of Sp1 to the cis-element will enhance transcription of renin gene. Thus, polymorphism within C-5312T might contribute to the reduction of renin transcription.

Entities:  

Year:  2013        PMID: 24497727      PMCID: PMC3910356          DOI: 10.6026/97320630091010

Source DB:  PubMed          Journal:  Bioinformation        ISSN: 0973-2063


Background

Uncontrolled hypertension has become a major health problem worldwide. Previous study reveals that the prevalence of uncontrolled hypertension in both developed and developing countries remains high [1]. Many studies suggest that uncontrolled hypertension leads to a half of coronary heart disease and cerebrovascular disease incidents [2]. Moreover, it contributes to 7.5 million deaths per year (13% of all death causes) [3]. Therefore, achieving blood pressure target is essential to reduce the mortality and morbidity of hypertension related diseases [4, 5, 6]. Many factors may contribute to uncontrolled hypertension, such as antihypertensive drug combination, patients' compliance, and genetic variants in renin angiotensin aldosterone system. Renin is an aspartyl protease produced and secreted by juxtaglomerular cell in kidney [7]. This enzyme induces enzymatic cascade that generates angiotensin II peptide as the main effector in the system of renin angiotensin aldosterone as blood pressure regulator [8]. Plasma renin level has been used for many years to determine the responses to antihypertensive therapy. The transcription level of renin is determined by many factors such as the presence of distal enhancer in renin gene and polymorphism in this area. Studies on human chorionic cultured cell suggest that renin distal enhancer plays a pivotal role in renin gene expression. Deletion of this area resulted in 10 fold loss of enhancer activity [9]. Fuchs, et al. suggest that SNP in C-5312T of renin enhancer increases transcription level of renin gene by 45% in -5312T compared to -5312C9 [10]. On the other hand, Pan L., et al. (2003) report that renin gene expression is regulated by Sp1/Sp3 proteins, mutations in these proteins decrease renin levels up to 40% in mice [9]. This phenomenon suggests that Sp1 acts as a positive regulatory protein that binds renin enhancer. Thus, this study has been designed to investigate whether renin enhancer has a Sp1-binding site, and to examine the influence of genetic variant of C-5312T on Sp1 binding pattern to renin enhancer.

Methodology

Detection of polymorphism:

SNP within renin distal enhancer of human renin gene was identified by direct sequencing of genomic DNA obtained from 34 hypertensive patients. Each sample was amplified by these primers 5'-CGTAGTGCCATTTTTAGGAAC-3' and 5'-AACACCA AAGCAGGCTTAA-3'. All samples were sequenced by automatic sequencing method (Macrogen) and the genetic variants were analyzed using Genescane software (Applied Biosystem). The existence of Sp1-binding site of these sequences was determined based on Sp1-binding site consensus from CORE Jaspar database (http://jaspar.genereg.net/cgi-bin/jaspar_db.pl).

DNA Modeling:

We generated 3D structural models of DNA from sequences of renin enhancer (5'gtgcccccagattaagcctg3') normal and (5'gtgccctcagattaagcctg3') mutant using 3D-DART provided by haddock (http://haddock.science.uu.nl/services/3DDART/) [11].

Molecular Docking:

Models of SP1 protein (1R8U) and ER-Estradiol (1A52) were retrieved from protein structure databases, PDB (http://www.rcsb.org). Binding interaction among molecule complex of ER-Estradiol, Sp1, and DNA was done by using Escher NG in VEGAZZ. Further for detailed analysis, we used Hex Protein Docking to predict interactions between Zinc Finger Domain 2 (Zf-2) of SP1 and DNA of renin enhancer. Hex is FFT-based approach that was first used as a rapid way to calculate shape complementarity within a 3D Cartesian grid [12]. Thereafter, the complex of docking result was analyzed using ligand Scout to know the amino acids and nucleotides responsible for the interaction [13].

Visualization:

All the visualization of the structure files was done using PyMol (www.pymol.org) and YASARA molecular graphics system.

Results

Proportions of genetic variant of the patients were CC (47.1%), CT (44.1%), and TT (8.8%). Sp1 protein is a trans-acting transcription factor-1, has 3 zinc finger domains which serves to bind DNA. Since the Sp1 bound to DNA in the GC rich motif, then we searched the motif in renin enhancer of 34 hypertensive patients that we analyzed. The data showed that renin enhancer of the hypertensive patients contained Sp1-DNA binding motif. Further, we found two genetic variations in Sp1-binding site from this study, SNPs in C-5312T (Figure 1).
Figure 1

Genetic variation of Sp1-binding site at hypertensive patients. Consensus of Sp1-binding site was retrieved from Jaspar CORE database (A), Varian renin enhancer at -5312C (B), and variants of the renin enhancer at -5312T (C).

Sp1 is activated by a complex of ER alpha receptor (ER) and 17β-Estradiol, and then binds DNA to stimulate transcription of the gene being regulated. Therefore, we used the ER-Estradiol-Sp1 complex to elucidate pattern of the regulator bind to renin enhancer by using docking methode. The docking results showed that Sp1 most preferably bind to DNA in GC rich sequence. Sp1 was bound in the center of the GC rich sequence and form bond with C base in -5312C variant. However, Sp1 was bound in downstream of the GC rich sequence in -5312T variant. Taken together the phenomenon, indicated that genetic variations C-5312T of renin enhancer causes differences of Sp1 binding to renin enhancer (Figure 2).
Figure 2

Complex molecules of 17β-Estradiol (cyan), ER (ed), Sp1 (blue) and the Renin Enhancer (gray) was resulted from docking analysis by using Escher NG in VEGAZZ. The presence of SNP in C-5312T has led to change the bonding pattern of Sp1 to renin enhancer. Sp1 bound to the major groove side of renin enhancer on-5312T (A), shifts to the minor grove on-5312C (B).

Furthermore, we analyzed more detail the differences of Sp1 binding pattern to SNPs in C-5312T of renin enhancer by docking Zinc Finger domain-2 of SP1 with 21 BP DNA containing the C-5312T SNP. The result indicated that change from T to C causing displacement of Sp1 binding site from center to dowstream of GC rich sequence, and Sp1 loss of contact with bases -5312 (Figure 3). The shift in the Sp1 binding suggested that Sp1 loos contact with the center of rich GC sequence, which was very likely not be able to stimulate transcription of renin gene. This result explained why the transcription level of renin gene in -5312T was higher by 45% compared to -5312C.
Figure 3

Binding pattern of Zinc Finger Domain of Sp1 (Pink) to renin enhancher (Grey) was identified by docking analysis using Hex 8, position of SNPs in C-5312T is shown in green (Left Panel). Interaction of Sp1 amino acids and DNA is indicated by arrows (Right Panel). Binding pattern of Zinc Finger Domain shifted from the middle of Sp1-binding site on - 5312T (A), to downstream of Sp1-binding site on -5312C (B).

Discussion

Renin angiotensin aldosterone system (RAAS) plays a pivotal role in blood pressure regulation [8]. Renin, that catalyzes angiotensinogen to angiotensin I, plays an essential role on blood pressure regulation and electrolyte homeostasis [14]. Plasma renin level has been used for many years to determine the responses to antihypertensive therapy. The transcription level of renin is determined by many factors such as the presence of distal enhancer in renin gene and polymorphism in this area. Several studies have been conducted to identify the single nucleotide polymorphism (SNP) in renin gene and its association with hypertension [15, 14, 16]. These studies suggested that polymorphism in intron 1 of renin gene is strongly correlated with hypertension in Caucasian [15]. Furthermore, SNP in renin distal enhancer at -5312 is associated with hypertension in whites [14, 16]. This SNP also becomes a major determinant of patients' response to angiotensin-receptor blocker therapy in Ireland and Japan. This study shows two polymorphisms in renin distal enhancer, in -5190 site and -5312 site. Previous study has reported the functionality of polymorphism in -5312 in Japan and French [10, 17]. Sp1 binds to GC rich promoter especially in CACCC box and -5312 area might be identified by Sp1. This transcription factor will be activated by ER alpha and 17β-Estradiol (E2) [18]. Thus, polymorphism within C-5312T might contribute to the reduction of renin transcription. Fuchs, et al. stated that polymorphism in this site increases transcription level by 45% in -5312T compared to that of -5312C [10]. However, these studies do not explain the mechanism of transcriptional level increase. Therefore, according to all of the results of the analyses, we concluded that Genetic variant of C-5312T has changed binding pattern of Sp1 to renin enhancer, which is very likely to influence Sp1 activity to stimulate expression of renin gene. Morever, this study helped to explain why SNP -5312C reduces expression levels of renin gene.

Conclusion

This study shows that Sp1 most preferably binds to DNA at the GC rich region. The genetic variants C-5312T has changed binding pattern of Sp1 to renin enhancer. This is likely to influence Sp1 activity to stimulate the expression of renin gene.
  16 in total

Review 1.  Physiology of kidney renin.

Authors:  Hayo Castrop; Klaus Höcherl; Armin Kurtz; Frank Schweda; Vladimir Todorov; Charlotte Wagner
Journal:  Physiol Rev       Date:  2010-04       Impact factor: 37.312

2.  LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters.

Authors:  Gerhard Wolber; Thierry Langer
Journal:  J Chem Inf Model       Date:  2005 Jan-Feb       Impact factor: 4.956

3.  Renin gene polymorphism: its relationship to hypertension, renin levels and vascular responses.

Authors:  Bei Sun; Jonathan S Williams; Luminita Pojoga; Bindu Chamarthi; Jessica Lasky-Su; Benjamin A Raby; Paul N Hopkins; Xavier Jeunemaitre; Nancy J Brown; Claudio Ferri; Gordon H Williams
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2011-04-13       Impact factor: 1.636

4.  Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements.

Authors:  B Saville; M Wormke; F Wang; T Nguyen; E Enmark; G Kuiper; J A Gustafsson; S Safe
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

5.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

6.  Renin gene polymorphisms and haplotypes, blood pressure, and responses to renin-angiotensin system inhibition.

Authors:  Niamh Moore; Patrick Dicker; John K O'Brien; Milos Stojanovic; Ronán M Conroy; Achim Treumann; Eoin T O'Brien; Desmond Fitzgerald; Denis Shields; Alice V Stanton
Journal:  Hypertension       Date:  2007-06-11       Impact factor: 10.190

7.  3D-DART: a DNA structure modelling server.

Authors:  Marc van Dijk; Alexandre M J J Bonvin
Journal:  Nucleic Acids Res       Date:  2009-05-05       Impact factor: 16.971

Review 8.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.

Authors:  M R Law; J K Morris; N J Wald
Journal:  BMJ       Date:  2009-05-19

Review 9.  Early detection and management of the high-risk patient with elevated blood pressure.

Authors:  Cristina Sierra; Alejandro de la Sierra
Journal:  Vasc Health Risk Manag       Date:  2008

10.  Genetic variant of the Renin-Angiotensin system and diabetes influences blood pressure response to Angiotensin receptor blockers.

Authors:  Tadashi Konoshita; Norihiro Kato; Sébastien Fuchs; Shinichi Mizuno; Chikako Aoyama; Makoto Motomura; Yasukazu Makino; Shigeyuki Wakahara; Isao Inoki; Isamu Miyamori; Florence Pinet
Journal:  Diabetes Care       Date:  2009-06-09       Impact factor: 17.152

View more
  1 in total

1.  Determinants of plasma renin activity: role of a human renin gene variant as a genetic factor.

Authors:  Tadashi Konoshita; Takahiro Nakaya; Ai Sakai; Mika Yamada; Mai Ichikawa; Satsuki Sato; Michiko Imagawa; Miki Fujii; Katsushi Yamamoto; Yasukazu Makino; Kenichiro Arakawa; Jinya Suzuki; Tamotsu Ishizuka
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.